{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:45:17Z","timestamp":1794332717967,"version":"4.9.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":1320,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1038\/s41379-018-0200-x","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T14:31:07Z","timestamp":1547044267000},"page":"830-843","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":108,"title":["Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma"],"prefix":"10.1016","volume":"32","author":[{"given":"Vignesh","family":"Shanmugam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel K.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.M.","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynette M.","family":"Sholl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6475-8345","authenticated-orcid":false,"given":"Jason L.","family":"Hornick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/s41379-018-0200-x_bib1","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood-2010-04-279083","article-title":"Recurrent BRAF mutations in Langerhans cell histiocytosis","volume":"116","author":"Badalian-Very","year":"2010","journal-title":"Blood"},{"key":"10.1038\/s41379-018-0200-x_bib2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2159-8290.CD-15-0913","article-title":"Diverse and targetable kinase alterations drive histiocytic neoplasms","volume":"6","author":"Diamond","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1038\/s41379-018-0200-x_bib3","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1038\/s41379-018-0200-x_bib4","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1200\/JCO.2014.57.1950","article-title":"Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease","volume":"33","author":"Haroche","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-018-0200-x_bib5","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1097\/01.pas.0000131541.95394.23","article-title":"Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy","volume":"28","author":"Hornick","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/s41379-018-0200-x_bib6","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/modpathol.2011.102","article-title":"Clonally related histiocytic\/dendritic cell sarcoma and chronic lymphocytic leukemia\/small lymphocytic lymphoma: a study of seven cases","volume":"24","author":"Shao","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1038\/s41379-018-0200-x_bib7","doi-asserted-by":"crossref","first-page":"5433","DOI":"10.1182\/blood-2007-11-124792","article-title":"Clonally related follicular lymphomas and histiocytic\/dendritic cell sarcomas: evidence for transdifferentiation of the follicular lymphoma clone","volume":"111","author":"Feldman","year":"2008","journal-title":"Blood"},{"key":"10.1038\/s41379-018-0200-x_bib8","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1016\/j.ejca.2015.06.109","article-title":"Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas","volume":"51","author":"Gounder","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1038\/s41379-018-0200-x_bib9","doi-asserted-by":"crossref","first-page":"e87062","DOI":"10.1172\/jci.insight.87062","article-title":"Institutional implementation of clinical tumor profiling on an unselected cancer population","volume":"1","author":"Sholl","year":"2016","journal-title":"JCI Insight"},{"key":"10.1038\/s41379-018-0200-x_bib10","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1101\/gr.107524.110","article-title":"The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data","volume":"20","author":"McKenna","year":"2010","journal-title":"Genome Res"},{"key":"10.1038\/s41379-018-0200-x_bib11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nbt.2514","article-title":"Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples","volume":"31","author":"Cibulskis","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1038\/s41379-018-0200-x_bib12","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1093\/nar\/gku1211","article-title":"BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers","volume":"43","author":"Abo","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"10.1038\/s41379-018-0200-x_bib13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/35085588","article-title":"Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas","volume":"412","author":"Pasqualucci","year":"2001","journal-title":"Nature"},{"key":"10.1038\/s41379-018-0200-x_bib14","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nature23291","article-title":"Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS","volume":"548","author":"Yao","year":"2017","journal-title":"Nature"},{"key":"10.1038\/s41379-018-0200-x_bib15","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.18632\/oncotarget.653","article-title":"Recurrent targets of aberrant somatic hypermutation in lymphoma","volume":"3","author":"Khodabakhshi","year":"2012","journal-title":"Oncotarget"},{"key":"10.1038\/s41379-018-0200-x_bib16","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00428-016-1965-2","article-title":"Somatic mutations in histiocytic sarcoma identified by next generation sequencing","volume":"469","author":"Liu","year":"2016","journal-title":"Virchows Arch"},{"key":"10.1038\/s41379-018-0200-x_bib17","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00428-017-2176-1","article-title":"Histiocytic and dendritic cell neoplasms: what have we learnt by studying 67 cases","volume":"471","author":"Facchetti","year":"2017","journal-title":"Virchows Arch"},{"key":"10.1038\/s41379-018-0200-x_bib18","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/leu.2015.319","article-title":"Cooperation of BRAFF595L and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling","volume":"30","author":"Kordes","year":"2016","journal-title":"Leukemia"},{"key":"10.1038\/s41379-018-0200-x_bib19","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.3324\/haematol.2017.179150","article-title":"Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma","volume":"103","author":"Voruz","year":"2018","journal-title":"Haematologica"},{"key":"10.1038\/s41379-018-0200-x_bib20","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1056\/NEJMc1511490","article-title":"Trametinib in histiocytic sarcoma with an activating MAP2K1 (MEK1) mutation","volume":"378","author":"Gounder","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1038\/s41379-018-0200-x_bib21","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1200\/JCO.2010.33.2312","article-title":"Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling","volume":"29","author":"Wagle","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-018-0200-x_bib22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/ng.2828","article-title":"High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias","volume":"46","author":"Waterfall","year":"2014","journal-title":"Nat Genet"},{"key":"10.1038\/s41379-018-0200-x_bib23","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature16967","article-title":"Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities","volume":"531","author":"Kerr","year":"2016","journal-title":"Nature"},{"key":"10.1038\/s41379-018-0200-x_bib24","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ng1156","article-title":"Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia","volume":"34","author":"Tartaglia","year":"2003","journal-title":"Nat Genet"},{"key":"10.1038\/s41379-018-0200-x_bib25","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.molonc.2014.06.001","article-title":"The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition","volume":"8","author":"Ardini","year":"2014","journal-title":"Mol Oncol"},{"key":"10.1038\/s41379-018-0200-x_bib26","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion\u2013positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1038\/s41379-018-0200-x_bib27","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1212\/WNL.0000000000000880","article-title":"Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib","volume":"83","author":"Idbaih","year":"2014","journal-title":"Neurology"},{"key":"10.1038\/s41379-018-0200-x_bib28","doi-asserted-by":"crossref","first-page":"19459","DOI":"10.1074\/jbc.M113.475087","article-title":"CBL linker region and RING finger mutations lead to enhanced granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling via elevated levels of JAK2 and LYN","volume":"288","author":"Javadi","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1038\/s41379-018-0200-x_bib29","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ccr.2010.09.008","article-title":"Myeloid leukemia development in c-Cbl RING finger mutant mice is dependent on FLT3 signaling","volume":"18","author":"Rathinam","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1038\/s41379-018-0200-x_bib30","doi-asserted-by":"crossref","first-page":"S2220","DOI":"10.1016\/j.jtho.2017.09.1489","article-title":"P3.01-048 CBL mutations as potential mediators of EGFR TKI resistance effectively treated with sitravatinib","volume":"12","author":"Bazhenova","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1038\/s41379-018-0200-x_bib31","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.1038\/sj.onc.1210175","article-title":"A short N-terminal sequence of PTEN controls cytoplasmic localization and is required for suppression of cell growth","volume":"26","author":"Denning","year":"2007","journal-title":"Oncogene"},{"key":"10.1038\/s41379-018-0200-x_bib32","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1084\/jem.20141759","article-title":"Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K","volume":"211","author":"Lucas","year":"2014","journal-title":"J Exp Med"},{"key":"10.1038\/s41379-018-0200-x_bib33","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.mrfmmm.2004.08.021","article-title":"INK4a\/ARF: a multifunctional tumor suppressor locus","volume":"576","author":"Sharpless","year":"2005","journal-title":"Mutat Res"},{"key":"10.1038\/s41379-018-0200-x_bib34","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/pbc.22810","article-title":"Pediatric histiocytic sarcoma clonally related to precursor B-cell acute lymphoblastic leukemia with homozygous deletion of CDKN2A encoding p16INK4A","volume":"56","author":"Kumar","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1038\/s41379-018-0200-x_bib35","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ccr.2006.03.028","article-title":"The PTEN and INK4A\/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans","volume":"9","author":"Carrasco","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1038\/s41379-018-0200-x_bib36","doi-asserted-by":"crossref","first-page":"19819","DOI":"10.18632\/oncotarget.4378","article-title":"Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1","volume":"6","author":"Gatalica","year":"2015","journal-title":"Oncotarget"},{"key":"10.1038\/s41379-018-0200-x_bib37","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/PAS.0000000000000590","article-title":"Expression of programmed cell death 1 ligands (PD-L1 and PD-L2) in histiocytic and dendritic cell disorders","volume":"40","author":"Xu","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/s41379-018-0200-x_bib38","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-018-0200-x_bib39","doi-asserted-by":"crossref","first-page":"e1185582","DOI":"10.1080\/2162402X.2016.1185582","article-title":"BRAF V600E mutation correlates with suppressive tumor immune microenvironment and reduced disease-free survival in Langerhans cell histiocytosis","volume":"5","author":"Zeng","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1038\/s41379-018-0200-x_bib40","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1038\/sj.leu.2403982","article-title":"Aberrant somatic hypermutation in primary mediastinal large B-cell lymphoma [16]","volume":"19","author":"Rossi","year":"2005","journal-title":"Leukemia"},{"key":"10.1038\/s41379-018-0200-x_bib41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/ejh.12755","article-title":"Histiocytic sarcoma as a secondary malignancy: pathobiology, diagnosis, and treatment","volume":"97","author":"Ansari","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1038\/s41379-018-0200-x_bib42","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/PAS.0b013e31819287b8","article-title":"High frequency of clonal immunoglobulin receptor gene rearrangements in sporadic histiocytic\/dendritic cell sarcomas","volume":"33","author":"Chen","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/s41379-018-0200-x_bib43","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"10.1038\/s41379-018-0200-x_bib44","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41379-018-0200-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41379-018-0200-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089339522201064X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089339522201064X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41379-018-0200-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:43:55Z","timestamp":1760229835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S089339522201064X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S089339522201064X"],"URL":"https:\/\/doi.org\/10.1038\/s41379-018-0200-x","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/s41379-018-0200-x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}